{"api":"v1","generated_at":"2026-10-02T17:35:48.643Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-gipss-43589a","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-gipss-43589a/at/2026-10-02T12-31Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-02T12:31:46.748Z","snapshot_stamp":"2026-10-02T12-31Z","endpoint":{"slug":"api-magentlab-com-api-calc-gipss-43589a","canonical_url":"https://api.magentlab.com/api/calc/gipss","resource":"https://api.magentlab.com/api/calc/gipss","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.4 y (94%), 8.0 y (73%), 4.2 y (40%), 2 y (14%). Not DIPSS or MIPSS70-plus. magent does not karyotype or sequence.","service_name":"magent","declared_category":null,"declared_tags":["gipss","myelofibrosis","hematology","prognosis","karyotype"],"route_template":null,"registry_updated":"2026-09-28T15:09:46.280Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc gipss","category":"other","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-02T12:31:46.748Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-02T12:31:46.748Z","calls_30d":1,"unique_payers_30d":1,"last_called_at":"2026-09-28T15:09:46.151Z"},"validation":{"latest":{"observed_at":"2026-10-02T14:18:28.013Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-02"},"uptime":[{"days":7,"observed":6,"passed":6,"ratio":1},{"days":30,"observed":6,"passed":6,"ratio":1},{"days":90,"observed":6,"passed":6,"ratio":1}],"history_90d":[{"observed_at":"2026-10-02T14:18:28.013Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-02","state_changed":false},{"observed_at":"2026-10-01T07:17:54.996Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T06:35:27.452Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T18:55:00.090Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T16:55:05.246Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-28","state_changed":false},{"observed_at":"2026-09-28T16:41:08.399Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["gipss","myelofibrosis","hematology","prognosis","karyotype"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/gipss","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T15:09:46.151Z","l30DaysTotalCalls":1,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/gipss","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"karyotype":"favorable","asxl1_mutated":false,"srsf2_mutated":false,"calr_type1_like":true,"u2af1_q157_mutated":false},{"karyotype":"favorable","asxl1_mutated":false,"srsf2_mutated":false,"calr_type1_like":true,"u2af1_q157_mutated":false}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/gipss","count":2,"items":[{"score":0,"formula":"gipss","citation":{"id":"tefferi-2018","doi":"10.1038/s41375-018-0107-z","pmid":"29654267","title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","source":"Leukemia. 2018;32(7):1631-1642","authors":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Vannucchi AM"},"karyotype":"favorable","max_score":6,"components":[{"value":"favorable","factor":"karyotype","points":0,"present":false},{"factor":"absence_of_calr_type1_like","points":0,"present":false},{"factor":"asxl1_mutated","points":0,"present":false},{"factor":"srsf2_mutated","points":0,"present":false},{"factor":"u2af1_q157_mutated","points":0,"present":false}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","risk_group":"low","asxl1_mutated":false,"srsf2_mutated":false,"calr_type1_like":true,"formula_expression":"GIPSS = karyotype (favorable 0, unfavorable 1, vhr 2) + absence of type 1/like CALR 1 + asxl1_mutated 1 + srsf2_mutated 1 + u2af1_q157_mutated 1; Tefferi 2018; max 6; low 0, intermediate_1 1, intermediate_2 2, high ≥3","u2af1_q157_mutated":false,"median_survival_years":26.4,"five_year_survival_percent":94},{"score":0,"formula":"gipss","citation":{"id":"tefferi-2018","doi":"10.1038/s41375-018-0107-z","pmid":"29654267","title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","source":"Leukemia. 2018;32(7):1631-1642","authors":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Vannucchi AM"},"karyotype":"favorable","max_score":6,"components":[{"value":"favorable","factor":"karyotype","points":0,"present":false},{"factor":"absence_of_calr_type1_like","points":0,"present":false},{"factor":"asxl1_mutated","points":0,"present":false},{"factor":"srsf2_mutated","points":0,"present":false},{"factor":"u2af1_q157_mutated","points":0,"present":false}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","risk_group":"low","asxl1_mutated":false,"srsf2_mutated":false,"calr_type1_like":true,"formula_expression":"GIPSS = karyotype (favorable 0, unfavorable 1, vhr 2) + absence of type 1/like CALR 1 + asxl1_mutated 1 + srsf2_mutated 1 + u2af1_q157_mutated 1; Tefferi 2018; max 6; low 0, intermediate_1 1, intermediate_2 2, high ≥3","u2af1_q157_mutated":false,"median_survival_years":26.4,"five_year_survival_percent":94}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["karyotype","calr_type1_like","asxl1_mutated","srsf2_mutated","u2af1_q157_mutated"],"properties":{"karyotype":{"enum":["favorable","unfavorable","vhr"],"type":"string","description":"Tefferi 2018 revised three-tier karyotype as assigned by the caller (mutually exclusive). favorable is a normal karyotype or sole 13q−, +9, 20q−, chromosome 1 translocation/duplication, or sex chromosome abnormality including −Y and scores 0. unfavorable is all other abnormalities and scores 1. vhr is very high risk: single/multiple −7, i(17q), inv(3)/3q21, 12p−/12p11.2, 11q−/11q23, +21, or other autosomal trisomies not including +8/+9 and scores 2. magent does not karyotype."},"asxl1_mutated":{"type":"boolean","description":"ASXL1 mutation as assigned by the caller (Tefferi 2018). true scores 1. magent does not sequence."},"srsf2_mutated":{"type":"boolean","description":"SRSF2 mutation as assigned by the caller (Tefferi 2018). true scores 1. magent does not sequence."},"calr_type1_like":{"type":"boolean","description":"Presence of a type 1/like CALR mutation as assigned by the caller (Tefferi 2018). false (absence) scores 1. true scores 0. Type 2/like CALR, JAK2, MPL, and triple-negative are absence of type 1/like CALR. magent does not sequence."},"u2af1_q157_mutated":{"type":"boolean","description":"U2AF1 Q157 mutation (Q157P or Q157R) as assigned by the caller (Tefferi 2018). true scores 1. U2AF1 S34 does not score. magent does not sequence."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.4 y (94%), 8.0 y (73%), 4.2 y (40%), 2 y (14%). Not DIPSS or MIPSS70-plus. magent does not karyotype or sequence.","lastUpdated":"2026-09-28T15:09:46.28Z","serviceName":"magent","x402Version":2}]}}